ESTRO 2025 - Abstract Book

S1767

Clinical – Upper GI

ESTRO 2025

Conclusion: The MTD was not reached in this study with no grade ≥3 toxicities reported at any dose level. Dose levels of 40 and 50 Gy could be delivered with high tumor coverages, but tumor coverage with doses of 60 Gy was highly dependent on favorable patient anatomy. These findings demonstrate the safety of delivering up to 60 Gy in five fractions using online adaptive MRgRT in the pancreatic area.

Keywords: MR-guided RT, dose escalation, pancreatic cancer

1363

Digital Poster Clinical outcomes of stereotactic body radiotherapy for hepatocellular carcinoma with macrovascular invasion in a predominantly non-viral cohort Jose Paul 1 , Cyriac Abby Philips 2 , John Menachery 3 , Sanju Cyriac 4 , Rajesh Sasidharan 5 , Ajith Toms 6 , Susan John 7 , Subi Thanath Subramanian 8 , Joseph George 9 , Renjith Thomas Rajan 1 , Ayesha Jaleel 1 , Arun Philip 4 , Aswin Joy 4 , Rosh Varghese 10 , Ajit Tharakan 10 , Rizwan Ahamed 10 , Tharun Tom Oomen 10 , Jacob Joseph 10 , Anand Ebin Thomas 8 , Teena Sleeba 6 , Merin Jose 6 , Geethu John 6 , Vijay Harish Somasundaram 11 , Latha K Abraham 12 , Philip Augustine 13 1 Department of Radiation Oncology, Rajagiri Hospital, Aluva, India. 2 Department of Clinical and Translational Hepatology, Rajagiri Hospital, Aluva, India. 3 Department of Hepatology and Transplant Hepatology, Rajagiri Hospital, Aluva, India. 4 Department of Medical Oncology, Rajagiri Hospital, Aluva, India. 5 Department of Interventional Radiology, Rajagiri Hospital, Aluva, India. 6 Department of Radiology, Rajagiri Hospital, Aluva, India. 7 Department of Clinical Epidemiology, Rajagiri Hospital, Aluva, India. 8 Department of Surgical Oncology, Rajagiri Hospital, Aluva, India. 9 Department of GI , HPB and Multiorgan Transplant Surgery, Rajagiri Hospital, Aluva, India. 10 Department of Medical Gastroenterology, Rajagiri Hospital, Aluva, India. 11 Department of Nuclear Medicine, Rajagiri Hospital, Aluva, India. 12 Department of Pathology, Rajagiri Hospital, Aluva, India. 13 Department of Gastroenterology and Advanced GI Endoscopy, Rajagiri Hospital, Aluva, India Purpose/Objective: Non viral etiology predominates Hepatocellular Carcinoma (HCC) patients in our region (1) distinct from North American / East Asian cohorts and is a minority in existing literature on Stereotactic Body Radiotherapy (SBRT) for HCC with macrovascular invasion (MVI) (2) . Aim of the study is to report clinical outcomes of SBRT in a large cohort of patients with HCC and MVI treated at our institution. Material/Methods: Patients diagnosed to have HCC with MVI who underwent SBRT at our institution between 1 st December 2019 and 30 th June 2024 were evaluated. Patients with extrahepatic disease, retroviral infection, prior rupture and active second malignancy were excluded. Primary outcome of interest was overall survival (OS). Progression free survival(PFS) and adverse events(AE) were secondary outcomes. Results: The study included 112 patients of which 103 were eligible for analysis. Baseline characteristics are summarized in Table 1.